Symptomtext
No additional AE reported; Caller reports that a four year old patient received the second dose of PROQUAD less than 4 weeks after receiving the first dose of proquad; This spontaneous report was received from nurse referring to 4-year-old patient of unknown gender. There was no information regarding the patient's pertinent medical history, historical drugs, concurrent conditions, concomitant therapies, and previous drug reactions or allergies. On 25-JAN-2022, the patient was vaccinated with first dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live(recombinant human albumin)) (PROQUAD), 0.5 ml (lot number # was reported as U022722 and expiration date was reported as 16-JAN-2023, route, anatomical location were not reported) and on 18-FEB-2022, the patient was vaccinated with second dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live(recombinant human albumin)) (PROQUAD), 0.5 ml less than four weeks after receiving the first dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (Inappropriate schedule of product administration)(lot number # was reported as U024510 and expiration date was reported as 02-FEB-2023, route, anatomical location were not reported) for prophylaxis. No additional adverse event was reported.